StreetInsider.com News Articles

MiniMed's Smallest App-Controlled Insulin Pump is Now Available in the U.S.

Wed, 17 Jun 2026 09:04:00 -0400

People with type 1 or insulin-requiring type 2 diabetes in the U.S. can now wear MiniMed's smallest pump, paired with the Simplera Sync™ sensor

NORTHRIDGE, Calif., June 17, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), today announced its first commercial launch of the MiniMed Flex™ system in the United States — its first app-controlled pump and the company's smallest insulin pump yet. The system launches with Simplera Sync™ sensor, a disposable, all-in-one sensor with easy two-step insertion. The launch with the Instinct sensor, made by Abbott, will follow later

MiniMed's Smallest App-Controlled Insulin Pump is Now Available in the U.S.

Wed, 17 Jun 2026 09:04:00 -0400

People with type 1 or insulin-requiring type 2 diabetes in the U.S. can now wear MiniMed's smallest pump, paired with the Simplera Sync™ sensor

MiniMed's Smallest App-Controlled Insulin Pump is Now Available in the U.S.

Wed, 17 Jun 2026 09:04:00 -0400

People with type 1 or insulin-requiring type 2 diabetes in the U.S. can now wear MiniMed's smallest pump, paired with the Simplera Sync™ sensor

MiniMed's Smallest App-Controlled Insulin Pump is Now Available in the U.S.

Wed, 17 Jun 2026 09:04:00 -0400

People with type 1 or insulin-requiring type 2 diabetes in the U.S. can now wear MiniMed's smallest pump, paired with the Simplera Sync™ sensor

MiniMed's Smallest App-Controlled Insulin Pump is Now Available in the U.S.

Wed, 17 Jun 2026 09:04:00 -0400

People with type 1 or insulin-requiring type 2 diabetes in the U.S. can now wear MiniMed's smallest pump, paired with the Simplera Sync™ sensor

MiniMed's Smallest App-Controlled Insulin Pump is Now Available in the U.S.

Wed, 17 Jun 2026 09:04:00 -0400

People with type 1 or insulin-requiring type 2 diabetes in the U.S. can now wear MiniMed's smallest pump, paired with the Simplera Sync™ sensor

MiniMed Group (MMED) Reiterated at Buy by Benchmark After ADA Meeting

Fri, 12 Jun 2026 07:23:52 -0400

Benchmark analyst Bruce Jackson reiterated a Buy rating and $20.00 price target on MiniMed Group (NASDAQ: MMED).

The analyst commented, "We caught up with MiniMed at the recent annual meeting of the American Diabetes Association (ADA) and are updating our model for FQ4. MiniMed formally launched two new products at ADA, the MiniMed Flex AID system and the MiniMed Go smart insulin pen. The two products are examples of MiniMed’s strategy to provide users with a complete selection of CGM and insulin delivery options that operate through a single app. The app helps retain users in the MiniMed ecosystem and provides

Benchmark Reiterates Buy Rating on MiniMed Group (MMED) Following Better-Than-Expected Q4

Thu, 04 Jun 2026 09:26:53 -0400

Benchmark analyst Bruce Jackson reiterated a Buy rating and $20.00 price target on MiniMed Group (NASDAQ: MMED).

The analyst commented, "MiniMed reported better than expected FQ4 results and introduced upbeat expectations for FY 2027 of about 10% organic revenue growth and Adjusted EBITDA margins of approximately 16%, primarily from operating expense efficiencies. Management expressed confidence in the guide due to three new products, the MiniMed Flex AID system, launching later this month, international availability of the Instinct CGM sensor for use with the 780G, launching later this month, and the MiniMed Go, a smart MDI system that launched in Europe earlier

Piper Sandler on MiniMed Group (MMED): 'Nice Start as a Public Entity but Still Plenty to Prove'

Thu, 04 Jun 2026 08:01:59 -0400

Piper Sandler analyst Matt O'Brien reiterated a Neutral rating and $16.00 price target on MiniMed Group (NASDAQ: MMED).

The analyst commented: "This morning, MiniMed reported fiscal Q4 financial results that beat on the top line. Management also provided initial FY'27 guidance which appears reasonable in our view given where the company finished the year though we still are more cautious on new product commercialization expectations. On a geographic basis, performance was mixed, with OUS strength leading the beat while US revenue fell short of expectations. The latter is a timing issue as many domestic customers delayed pump purchases until Flex launches

MiniMed Group (MMED) PT Lowered to $22 at Wells Fargo

Thu, 04 Jun 2026 06:43:28 -0400

Wells Fargo analyst Larry Biegelsen lowered the price target on MiniMed Group (NASDAQ: MMED) to $22.00 (from $26.00) while maintaining a Overweight rating.

Form 8-K MiniMed Group, Inc. For: Jun 03

Wed, 03 Jun 2026 06:51:00 -0400

si-local-file:///var/storage/secattach/20260603/26595107.html

MiniMed partners with Abbott for dual glucose-ketone sensors

Wed, 03 Jun 2026 06:49:14 -0400

MiniMed (NASDAQ: MMED) announced an expanded agreement with Abbott to commercialize dual glucose-ketone sensors that will integrate with MiniMed's smart dosing systems. The sensors are designed to monitor both glucose and ketone levels continuously to help prevent diabetic ketoacidosis, a life-threatening complication.

The new sensors will be the same size as Abbott's existing Instinct sensor and will work with MiniMed's automated insulin delivery and Smart MDI systems. The partnership builds on the companies' existing collaboration for the Instinct sensor.

"By integrating dual glucose-ketone monitoring sensors with our MiniMed smart dosing systems, we're adding an additional layer of intelligence and protection," said Que

MiniMed to Expand Sensor Portfolio with Integrated Dual Glucose-Ketone Sensors Made by Abbott

Wed, 03 Jun 2026 06:47:00 -0400

Agreement builds on the companies' ongoing partnership to expand choice and simplify diabetes management

NORTHRIDGE, Calif., June 3, 2026 /PRNewswire/ -- MiniMed (NASDAQ: MMED), a global leader in diabetes technology, today announced an expanded agreement with Abbott to collaborate on commercializing dual glucose-ketone sensors designed to integrate exclusively with MiniMed smart dosing systems.

MiniMed to Expand Sensor Portfolio with Integrated Dual Glucose-Ketone Sensors Made by Abbott

Wed, 03 Jun 2026 06:47:00 -0400

Agreement builds on the companies' ongoing partnership to expand choice and simplify diabetes management

MiniMed to Expand Sensor Portfolio with Integrated Dual Glucose-Ketone Sensors Made by Abbott

Wed, 03 Jun 2026 06:47:00 -0400

Agreement builds on the companies' ongoing partnership to expand choice and simplify diabetes management

MiniMed to Expand Sensor Portfolio with Integrated Dual Glucose-Ketone Sensors Made by Abbott

Wed, 03 Jun 2026 06:47:00 -0400

Agreement builds on the companies' ongoing partnership to expand choice and simplify diabetes management

MiniMed to Expand Sensor Portfolio with Integrated Dual Glucose-Ketone Sensors Made by Abbott

Wed, 03 Jun 2026 06:47:00 -0400

Agreement builds on the companies' ongoing partnership to expand choice and simplify diabetes management

MiniMed to Expand Sensor Portfolio with Integrated Dual Glucose-Ketone Sensors Made by Abbott

Wed, 03 Jun 2026 06:47:00 -0400

Agreement builds on the companies' ongoing partnership to expand choice and simplify diabetes management

MiniMed Delivers Strong Fourth Quarter and Full Fiscal Year 2026 Financial Results; Provides Fiscal Year 2027 Outlook

Wed, 03 Jun 2026 06:46:00 -0400

Continued momentum in Q4, with net sales of $837 million growing 16% as reported and 9% organic year-over-year
Record annual net sales performance surpasses $3B for first time, growing 14% as reported and 8% organic
Advanced global pipeline ahead of schedule with FDA clearance for MiniMed Flex™, CE Mark for Instinct, and global launch of MiniMed Go™ Smart MDI

NORTHRIDGE, Calif., June 3, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today reported financial results for its fourth quarter and full fiscal year ended April 24, 2026.

MiniMed Delivers Strong Fourth Quarter and Full Fiscal Year 2026 Financial Results; Provides Fiscal Year 2027 Outlook

Wed, 03 Jun 2026 06:46:00 -0400

Continued momentum in Q4, with net sales of $837 million growing 16% as reported and 9% organic year-over-year
Record annual net sales performance surpasses $3B for first time, growing 14% as reported and 8% organic
Advanced global pipeline ahead of schedule with FDA clearance for MiniMed Flex™, CE Mark for Instinct, and global launch of MiniMed Go™ Smart MDI

MiniMed to Showcase MiniMed Flex™ and MiniMed Go™ at the American Diabetes Association Scientific Sessions

Wed, 27 May 2026 09:07:00 -0400

Following this week's launch of MiniMed Go™, MiniMed will bring hands-on demonstrations of the system and new clinical data

NORTHRIDGE, Calif., May 27, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced an overview of its upcoming presence at the American Diabetes Association's (ADA) Scientific Sessions in New Orleans June 5-8. The meeting marks MiniMed's first U.S. diabetes congress since becoming a standalone public company — and the first to feature its newest generation of technology designed to give people with diabetes more freedom every

MiniMed to Showcase MiniMed Flex™ and MiniMed Go™ at the American Diabetes Association Scientific Sessions

Wed, 27 May 2026 09:07:00 -0400

Following this week's launch of MiniMed Go™, MiniMed will bring hands-on demonstrations of the system and new clinical data

MiniMed to Showcase MiniMed Flex™ and MiniMed Go™ at the American Diabetes Association Scientific Sessions

Wed, 27 May 2026 09:07:00 -0400

Following this week's launch of MiniMed Go™, MiniMed will bring hands-on demonstrations of the system and new clinical data

MiniMed to Showcase MiniMed Flex™ and MiniMed Go™ at the American Diabetes Association Scientific Sessions

Wed, 27 May 2026 09:07:00 -0400

Following this week's launch of MiniMed Go™, MiniMed will bring hands-on demonstrations of the system and new clinical data

MiniMed to Showcase MiniMed Flex™ and MiniMed Go™ at the American Diabetes Association Scientific Sessions

Wed, 27 May 2026 09:07:00 -0400

Following this week's launch of MiniMed Go™, MiniMed will bring hands-on demonstrations of the system and new clinical data